Ask AI
ProCE Banner Activity

Optimizing Transplant Outcomes Through Contemporary CMV Management: Strategies to Address Clinical Challenges in Treatment of Refractory or Resistant Disease

Slideset

Download these slides curated by expert faculty to learn about optimizing antiviral regimens for CMV infections in HCT recipients.

Released: February 04, 2026

Continue Activity

Share

Provided by

 Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical specialists, including physicians, clinical pharmacists, advanced practice providers, and other healthcare professionals who care for HCT recipients with CMV infections.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the comprehensive burden of CMV replication on post-HCT clinical courses

  • Update strategies for timely identification of HCT recipients with, or at risk for, CMV infections with inadequate response to initial therapies

  • Modify antiviral therapy in HCT recipients experiencing treatment-limiting toxicities

  • Optimize antiviral regimens for treatment-refractory CMV infections in post-HCT settings